Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
UCB-derived Dual-target BCMA/CD19 CAR-T in Relapsed/Refractory Multiple Myeloma
Details : UCAR-T Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 24, 2025
Lead Product(s) : UC101
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : VectorBuilder
Deal Size : Inapplicable
Deal Type : Inapplicable
VectorBuilder Enables FDA IND for Cord Blood CAR-T Therapy
Details : UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. It is being evaluated to alleviate the risk of host-versus-graft response.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : UC101
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : VectorBuilder
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AT19
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Matrix Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Ucello Therapeutics Completes US$25 Million Series A Financing
Details : Proceeds from the financing will be used to advance the company's development of CAR-T technology platform CBT-X20, progress programs including lead asset AT19 through to US and China IND filings, and build a state of the art GMP-ready clinical manufactu...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
February 10, 2022
Lead Product(s) : AT19
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Matrix Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Contact Us!
Reset All
